Zymeworks, a company focused on managing drug royalties, has agreed to acquire fellow biotech Theravance in a deal valued at $929 million.
The purchase comes at a low point for Theravance. According to BioPharma Dive, the buyout follows a "strategic review" that the company launched after one of its drugs — a treatment for a type of low blood pressure — failed in the clinic. Endpoints News reports that Theravance had been "clearly running out of steam," having twice downsized its operations and absorbed repeated setbacks.
That troubled backdrop raises an obvious question: why pay nearly $1 billion for a company on the ropes? Endpoints News spoke with Zymeworks' CEO, who argued the deal is "value for money" despite the steep headline price. The logic ties to Zymeworks' identity as a royalty management company, as described by BioPharma Dive — a business model built around owning streams of income from drugs rather than chasing the next blockbuster in the lab.
In other words, where investors saw a biotech whose pipeline kept stumbling, Zymeworks appears to see a portfolio of revenue-generating assets worth acquiring.
The sources provided here do not detail which specific royalties or programs Zymeworks is buying, the structure of the payment, or when the deal is expected to close.
Why it matters: the acquisition is a clear example of how the biotech industry recycles value, with royalty-focused buyers stepping in to extract worth from companies whose drug-development bets have soured.